研究进展的结构和抗结肠直肠恶性瘤shikonin的特性

Jinghua Chen1,2, Jie Liu3, Weiwei Nie1

  • 1Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China.

概括

石康宁作为结直肠癌 (CRC) 的抗癌剂显示出希望. 这篇评论探讨了Shikoninonin的情况.